1 / 7

Authors: Hahn NM et al, ASCO 2009. Reviewed by: Dr. Lori Wood Abstract: 5018

A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC): Hoosier Oncology Group GU-0475. Authors: Hahn NM et al, ASCO 2009. Reviewed by: Dr. Lori Wood Abstract: 5018 Date posted: June 12, 2009.

lillian-beasley
Download Presentation

Authors: Hahn NM et al, ASCO 2009. Reviewed by: Dr. Lori Wood Abstract: 5018

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Multicentre Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) as First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC): Hoosier Oncology Group GU-0475 Authors: Hahn NM et al, ASCO 2009. Reviewed by: Dr. Lori Wood Abstract: 5018 Date posted: June 12, 2009

  2. Treatment Cisplatin 70 mg/m2 Gemcitabine 1250 mg/m2 d1 and d8* Bevacizumab 15 mg/kg d1 q21 days x 8 R *After first 17 patients,  venous thromboembolic events and Gemcitabine  to 1000 mg/m2. metastatic urothelial cancer ECOG 0-1 first-line 1 endpoint = PFS (by RECIST) n = 40 to  PFS from 7.5m  11.25m

  3. STUDY RATIONALE • Cisplatin/Gemcitabine would be considered standard first-line chemotherapy for metastatic urothelial cancer in North America. • Adding more chemotherapy (i.e.: the triplet of Gemcitabine/Cisplatin/Taxol) did not improve outcome in a previous phase III study. Unlikely to be further advantages to adding more/other chemotherapy drugs. • Therefore, reasonable to add targeted therapy to traditional chemotherapy •  VEGF expression associated with poor prognosis in bladder cancer. • So, combination of Gemcitabine/Cisplatin and Bevacizumab studied

  4. RESULTS • n = 43 • Median 6 cycles; 30% received all 8 and received maintenance Bevacizumab • Dose modifications 60% • Discontinued secondary to toxicity 42%  21% secondary to DVT/PE • Gemcitabine: • 1250 mg/m2 = 39% grade 3-4 DVT/PE and 0% grade 3-4 hemorrhage • 1000 mg/m2 = 8% grade 3-4 DVT/PE and 12% grade 3-5 hemorrhage • Deaths = 3 (sudden cardiac, aortic dissection, CNS hemorrhage)

  5. RESULTS (CONTINUED) • RECIST response rates: • CR = 14% • PR = 44% • SD = 30% • PD = 9% • PFS = 8.2 months with median follow-up 14.6m • PFS at 12m = 29% • Overall survival = 19.1 months • Overall survival at 12m = 65%

  6. STUDY COMMENTARY • Significant toxicity with this combination, especially DVT/PE. • CR + PR = 58% with PFS = 8.2m and OS = 19.1m. • The PFS and OS is higher than with Gemcitabine/Cisplatin alone; however, these were highly selected patients. • Currently an ongoing phase I study of Carboplatin/Gemcitabine/ Bevacizumab.

  7. BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS • This triplet is far from prime time. • It is very important in the metastatic palliative setting to “do no harm” and this combination looks like it does/could. • Another example of how the tolerability of systemic therapy in patients with bladder cancer is different than other cancer populations • i.e.: lung cancer: doses of Carboplatin/Gemcitabine are an AUC = 6 and full dose Gemcitabine • i.e.: bladder cancer: just cannot get those doses in because of myelosuppression • Tough combination to move into a phase III study.

More Related